<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03116932</url>
  </required_header>
  <id_info>
    <org_study_id>Puerto Rico PrEP Study-Part A</org_study_id>
    <nct_id>NCT03116932</nct_id>
  </id_info>
  <brief_title>Evaluating the Feasibility and Acceptability of Implementing a PrEP Program in PR-CoNCRA (San Juan, Puerto Rico)- Part A</brief_title>
  <official_title>Evaluating the Feasibility and Acceptability of Implementing a PrEP Program in PR-CoNCRA (San Juan, Puerto Rico)- Part A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Puerto Rico Community Network for Clinical Research on AIDS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Puerto Rico Community Network for Clinical Research on AIDS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The target population for this project will be men-who-have-sex-with-men (MSM) at high risk
      of HIV acquisition
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      225 high risk MSM will be interviewed to understand the knowledge and acceptability of
      pre-exposure prophylaxis (PrEP) in this population in Puerto Rico. A 187 item questionnaire
      will administered which will evaluate socio-demographic information, sexual conducts, PrEP
      knowledge and PrEP acceptability.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PrEP acceptability using a PrEP knowledge and acceptability questionnaire.</measure>
    <time_frame>One visit</time_frame>
    <description>Measure the degree of acceptance of PrEP in the study subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PrEP knowledge using a PrEP knowledge and acceptability questionnaire.</measure>
    <time_frame>One visit</time_frame>
    <description>Measure the level of education of the study subjects in the topic of PrEP using a questionnaire.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">225</enrollment>
  <condition>HIV/AIDS</condition>
  <arm_group>
    <arm_group_label>Part A - high risk MSM</arm_group_label>
    <description>Part A will consist of a descriptive analysis of the acceptability and knowledge on the topic of PrEP of the individuals that undergo routine HIV testing and counseling in study facilities or through outreach activities.
Part A will be focused only on high risk MSM. For this part of the study, 225 high risk will be interviewed to understand the knowledge and acceptability of PrEP in this population in Puerto Rico.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>PrEP knowledge and acceptability questionnaire</intervention_name>
    <description>This questionnaire consists of 187 items and evaluates socio-demographic variables, sex conducts, PrEP knowledge and PrEP acceptability.</description>
    <arm_group_label>Part A - high risk MSM</arm_group_label>
  </intervention>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      Dried Blood Spots are obtained at 2 time points for participants in part B in order to assess
      adequate drug levels are retained for bulk shipping for processing at collaborating lab.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        225 high risk men who have sex with men, HIV- subjects, 21 years or older , will be
        enrolled in Part A
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        INCLUSION CRITERIA;

        Study subjects who meet the following inclusion criteria will be considered for enrollment
        for Part A:

          1. age 21 years or older

          2. understand and sign the informed consent form and willing to participate in the study

          3. male or transgender female

          4. has one of the following risk factors:

               -  a high risk MSM as defined by:

               -  having unprotected sexual intercourse with at least two male partners in the past
                  6 months, or

               -  diagnosed with an STI in the past 6 months.

        PART A - EXCLUSION CRITERIA:

        Subjects with any of the following will not be considered for enrollment in Part A:

          1. Age younger than 21 years old

          2. Unable or unwilling to provide an informed consent

          3. Female gender at birth

          4. Do not meet the high risk criteria
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male-to-female transgender subjects are eligible for enrollment</gender_description>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vivian Tamayo-Agrait, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>787-753-9443</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Puerto Rico Community Network for Clinical Research on AIDS (PR-CoNCRA)</name>
      <address>
        <city>San Juan</city>
        <zip>00928</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2017</study_first_submitted>
  <study_first_submitted_qc>April 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2017</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Puerto Rico Community Network for Clinical Research on AIDS</investigator_affiliation>
    <investigator_full_name>Vivian Tamayo-Agrait, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>HIV prevention, high risk MSM, PrEP</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

